My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
June 2016
FROM THE PRESIDENT
Antimicrobial Resistance: Persistence Pays Off With This Strategic Priority
For over a decade, IDSA has mobilized key leaders and resources around the issue of antimicrobial resistance. Through legislative, regulatory, advocacy, and public awareness efforts, we have brought together like-minded organizations and agencies to join in the fight. The recent discovery of colistin-resistant bacteria in a Pennsylvania woman is a reminder that there is still much work to be done. Here’s a brief look back (with an eye toward the future).
TOP STORIES
New IDSA Guideline on Diagnosis and Treatment of Aspergillosis
An updated IDSA guideline on the diagnosis and treatment of aspergillosis has been published in Clinical Infectious Diseases. The updated guideline focuses on the diagnosis and treatment of the major forms of aspergillosis: allergic, chronic and invasive, the latter which kills 40 percent to 80 percent of those with widespread infection. According to the guideline, new therapies are improving care, but early diagnosis remains critical in the effective treatment of the potentially deadly fungal infection.
OPAT Handbook Now Available in Interactive, Digital Format
IDSA and CRG Publishing, a division of The Curry Rockefeller Group, LLC, have released the third edition of Handbook of Outpatient Parenteral Antimicrobial Therapy for Infectious Diseases, which provides ID specialists the tools they need to set up and provide OPAT. For the first time, the resource is available as an eHandbook that allows for easy updates, access and review. The eHandbook covers topics including: infections amenable to OPAT, OPAT use in pediatrics, legal and reimbursement issues, and OPAT and health care reform.
Donít Miss the Meeting Everyone Will be Talking About at IDWeek 2016!
Join a lively discussion with colleagues, learn about what IDSA and HIVMA are doing to promote the field of infectious diseases to medical students, residents, payers and policymakers, and contribute your opinions and ideas about the future of ID. We want to hear from YOU. Town Hall Meeting: Securing the Future of ID will be held on Friday, October 28 during IDWeek in New Orleans.
Upcoming dates to remember


The combined meeting of IDSA, SHEA, HIVMA, and PIDS, Oct. 26-30, 2016, in New Orleans. See you there!

  • Discounted Early Registration Deadline: July 29
PATIENT CARE AND SCIENCE
FDA Alerts Health Facilities of M. Chimaera Due to Heater-cooler devices; CDC Continued Updates on Zika Testing
Guidelines Survey: Please Take 10 Minutes to Share Your Feedback
CLINICAL PRACTICE MANAGEMENT
Antimicrobial Stewardship Programs via Telehealth
IDSA Webinar Explains CMSís Proposed New Payment Program
POLICY AND ADVOCACY
IDSA Continues to Drive Legislative Progress on Antimicrobial Resistance
Zika Funding Remains in Limbo
Senate Bill Would Increase Funding for Antibiotic Resistance, But Impose Cuts Elsewhere
HIVMA Endorses the Equality Act
GLOBAL HEALTH
Science Speaks Covers UN Meeting on Ending AIDS
EDUCATION AND RESOURCES
IDWeek Mentorship Program
IDSA Foundation Offers Three Research Awards in 2016
HIVMA Medical Student Program Aims to Inspire Careers in HIV
Support IDSA Foundation Through CFC
ABIM Seeks Your Input on MOC Exams
New CDC and Mass General Resource Helps Travelers Stay Healthy
FROM THE PRESIDENT
Antimicrobial Resistance: Persistence Pays Off With This Strategic Priority
TOP STORIES
New IDSA Guideline on Diagnosis and Treatment of Aspergillosis
OPAT Handbook Now Available in Interactive, Digital Format
Donít Miss the Meeting Everyone Will be Talking About at IDWeek 2016!
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.

Unsubscribe here